About the Company
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and inflammatory disorders, including psoriasis. vTv's development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), renal disease, and primary mitochondrial myopathy.
Employees
25
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VTVT News
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first ...
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
HIGH POINT, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399 ...
vTv Therapeutics Inc. Cl A
1 Day VTVT 6.30% DJIA -0.35% Russell 2K -1.96% Health Care/Life Sciences -0.13% ...
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused ...
VTv Therapeutics: Q4 Earnings Snapshot
HIGH POINT, N.C. — HIGH POINT, N.C. — VTv Therapeutics Inc. (VTVT) on Wednesday reported a loss of $3.5 million in its fourth quarter. The High Point, North Carolina-based company said it had ...
vTv Therapeutics Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
vTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy ...
Loading the latest forecasts...